Minerva Neurosciences, Inc
NERVMinerva Neurosciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders. The company's pipeline includes treatments targeting conditions such as schizophrenia, cognitive impairment, and other central nervous system disorders. Minerva aims to address unmet medical needs through novel drug candidates and has a focus on advancing neuroscience research.
Company News
Minerva Neurosciences announced that CEO Remy Luthringer will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder treatments, currently initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia.
Minerva Neurosciences reported FY2025 results with a net loss of $293.4 million (primarily due to $321.5 million in non-cash warrant and preferred stock issuance expenses). The company secured $80 million in gross proceeds from a private placement in October 2025 and plans to initiate a confirmatory Phase 3 trial for roluperidone for negative sym...
Minerva Neurosciences secured a $200 million funding agreement to support its Phase 3 trial for roluperidone, a drug targeting negative symptoms of schizophrenia. The funding includes immediate $80 million and potential additional tranches, with investors like Vivo Capital and Janus Henderson participating.
The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.
Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.
